September 10, 2024
The drug development landscape is rapidly evolving, with new regulatory guidance, novel therapy types, and exciting AI-powered technologies altering the face of clinical testing.
In this webcast, Scott Gottlieb, former FDA commissioner, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest in regulatory and biomarker development.
Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improve medical outcomes, reshape healthcare delivery, and expand consumer choice and safety. He is currently a partner at the venture capital firm New Enterprise Associates; a resident fellow at the American Enterprise Institute; a contributor to CNBC; and a board member to Pfizer, Inc. and Illumina, Inc.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
September 10, 2024
The drug development landscape is rapidly evolving, with new regulatory guidance, novel therapy types, and exciting AI-powered technologies altering the face of clinical testing.
In this webcast, Scott Gottlieb, former FDA commissioner, joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest in regulatory and biomarker development.
Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improve medical outcomes, reshape healthcare delivery, and expand consumer choice and safety. He is currently a partner at the venture capital firm New Enterprise Associates; a resident fellow at the American Enterprise Institute; a contributor to CNBC; and a board member to Pfizer, Inc. and Illumina, Inc.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
May 28, 2024
CellCarta’s poster, presented at ASCO 2024, discusses the study on tumor-specific MHC class II upregulation in patients with urothelial cancer undergoing anti-PD-L1 therapy.
The study, part of the abacus trial (NCT02662309), revealed that MHC class II expression in tumor cells, although rare, is associated with a positive response to atezolizumab. Utilizing spatial transcriptomics and immunohistochemistry (IHC), the research highlighted significant differences in MHC II expression between patients with pathological complete response (pCR) and those with major pathological response (MPR) or relapse.
The findings suggest that MHC II expression could serve as a biomarker for predicting therapeutic outcomes in bladder cancer treatment.
View the full poster:
May 28, 2024
CellCarta’s poster, presented at ASCO 2024, discusses the study on tumor-specific MHC class II upregulation in patients with urothelial cancer undergoing anti-PD-L1 therapy.
The study, part of the abacus trial (NCT02662309), revealed that MHC class II expression in tumor cells, although rare, is associated with a positive response to atezolizumab. Utilizing spatial transcriptomics and immunohistochemistry (IHC), the research highlighted significant differences in MHC II expression between patients with pathological complete response (pCR) and those with major pathological response (MPR) or relapse.
The findings suggest that MHC II expression could serve as a biomarker for predicting therapeutic outcomes in bladder cancer treatment.
View the full poster:
May 4, 2024
CellCarta’s poster on M-Protein analysis in plasma of multiple myeloma (MM) patients highlights the use of intact mass spectrometry for monitoring disease progression. This non-invasive method, requiring only a small volume of plasma or serum, measures M-Protein levels with high sensitivity, precision, and reproducibility.
The study demonstrated that mass spectrometry could detect significant reductions in M-Protein concentration, providing an effective alternative to bone marrow biopsies for evaluating treatment response and measurable residual disease (MRD). The workflow supports high-frequency sampling, offering a comprehensive profile of disease progression and treatment efficacy in MM patients.
View the poster
M-Protein Analysis in Plasma of Multiple Myeloma Patients by Intact Mass Spectrometry
May 4, 2024
CellCarta’s poster on M-Protein analysis in plasma of multiple myeloma (MM) patients highlights the use of intact mass spectrometry for monitoring disease progression. This non-invasive method, requiring only a small volume of plasma or serum, measures M-Protein levels with high sensitivity, precision, and reproducibility.
The study demonstrated that mass spectrometry could detect significant reductions in M-Protein concentration, providing an effective alternative to bone marrow biopsies for evaluating treatment response and measurable residual disease (MRD). The workflow supports high-frequency sampling, offering a comprehensive profile of disease progression and treatment efficacy in MM patients.
View the poster
M-Protein Analysis in Plasma of Multiple Myeloma Patients by Intact Mass Spectrometry
April 8, 2024
CellCarta’s proof-of-concept study utilizes the RareCyte CTC platform to enumerate large oncosomes (LOs) in patients with HER2 overexpressing tumors.
The study demonstrates that combining circulating tumor cells (CTCs), LOs, and circulating cell-free DNA (cfDNA) in a multimodal liquid biopsy analysis enhances the detection and monitoring of HER2 amplification in metastatic breast cancer.
The results showed a strong correlation between LO count and CTC count, and the combined analysis improved the accuracy of HER2 status assessment. This approach offers a cost-efficient and non-invasive method to monitor tumor biomarkers, providing valuable insights into tumor progression and treatment response.
View the poster:
Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform
April 8, 2024
CellCarta’s proof-of-concept study utilizes the RareCyte CTC platform to enumerate large oncosomes (LOs) in patients with HER2 overexpressing tumors.
The study demonstrates that combining circulating tumor cells (CTCs), LOs, and circulating cell-free DNA (cfDNA) in a multimodal liquid biopsy analysis enhances the detection and monitoring of HER2 amplification in metastatic breast cancer.
The results showed a strong correlation between LO count and CTC count, and the combined analysis improved the accuracy of HER2 status assessment. This approach offers a cost-efficient and non-invasive method to monitor tumor biomarkers, providing valuable insights into tumor progression and treatment response.
View the poster:
Proof-of-concept study to enumerate large oncosomes using the RareCyte CTC platform
